Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Abbott Labs...

    Abbott Labs first-quarter sales ahead of expectations

    GarimaWritten by Garima Published On 19 April 2019 3:30 AM  |  Updated On 19 April 2019 3:30 AM
    Abbott Labs first-quarter sales ahead of expectations

    Abbott Laboratories, whose products range from medical devices to infant nutritional formula posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share.


    New Delhi: Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double-digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.


    "The decisions we made three, five, seven years ago - and the ones we're making today - are driving positive long-term outlooks for all of our businesses," said Chief Executive Officer Miles White.


    Read Also: GUILTY: Abbott Healthcare did not pass Rs 96.59 lakh GST benefit to consumers


    The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share.


    Net sales rose to $7.54 billion from $7.39 billion. Analysts had expected $7.47 billion, according to IBES data from Refinitiv.


    Read Also: Abbott introduces diagnostic test Determine HBsAg 2 to accelerate hepatitis B care

    AbbottAbbott Laboratoriesblood sugarBPFreeStyle LibreFreestyle Libre glucose monitoring deviceglucoseglucose monitoring deviceHealthcareheart valvesIBESinfant nutritional formulaMedical DevicesMiles WhiteRefinitivRefinitiv datasurgerysurgical procedures
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok